MedTrace Logo

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

NCT04255602 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2120

Last updated 2023-12-07

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

Conditions

  • Acute Coronary Syndrome
  • Coronary Stent Implantation

Interventions

DRUG

Ticagrelor 60mg

Ticagrelor 60mg plus Aspirin 100mg for experimental group

DRUG

Ticagrelor 90mg

Ticagrelor 90mg plus Aspirin 100mg for active comparator group

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • Shanghai Tong Ren Hospital

    lead OTHER

Principal Investigators

  • Junbo Ge, Doctor · Fudan University

  • Lei Hou, Doctor · Shanghai Tongren Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-19
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04255602 on ClinicalTrials.gov